Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base.
Girones R, Aparicio J, Roure P, Germa-Lluch JR, García Del Muro X, Vazquez-Estevez S, Saenz A, Sastre J, Arranz Arija J, Gallardo E, Gonzalez-Billalabeitia E, Sanchez-Hernandez A, Terrasa J, Hernandez A, Santander C, Cillan E, Sagastibelza N, Almenar-Cubells D, Lopez Brea M, Maroto JP; Spanish Germ Cell Cancer Group (SGCCG). Girones R, et al. Clin Transl Oncol. 2014 Nov;16(11):959-65. doi: 10.1007/s12094-014-1179-5. Epub 2014 Apr 10. Clin Transl Oncol. 2014. PMID: 24719184
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Ryan CJ, et al. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Pérez-Valderrama B, et al. Among authors: arranz arija ja. Ann Oncol. 2016 Apr;27(4):706-11. doi: 10.1093/annonc/mdv601. Epub 2015 Dec 9. Ann Oncol. 2016. PMID: 26658889 Free article. Clinical Trial.
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D. Climent MÁ, et al. Among authors: arranz arija ja. Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2. Eur J Cancer. 2017. PMID: 29102858 Clinical Trial.
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. Among authors: arranz arija ja. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.
[Chemotherapy in prostatic carcinoma].
Pérez Manga G, Arranz Arija JA, García Gómez R, Salinas Hernández P, González del Val R. Pérez Manga G, et al. Among authors: arranz arija ja. Arch Esp Urol. 1993 Mar;46(2):116-26. Arch Esp Urol. 1993. PMID: 8498851 Review. Spanish.
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.
33 results